ArticleCureus2026
Clinical Predictors of Drug-Resistant Epilepsy in Adults: An Analytical Observational Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Drug-resistant epilepsy (DRE) remains a significant clinical challenge, with many adults experiencing persistent seizures despite adequate trials of antiseizure medications. Early identification of factors associated with DRE is essential for timely intervention and optimized management. Objectives The research aimed to examine the demographic, clinical, and behavioral factors involved with DRE in adults and to establish the difference in the severity of seizures, treatment adherence, and illness-specific characteristics of the patients with and without DRE. Methods An analytical observational study was conducted on 460 adults with epilepsy in Lahore, Pakistan. Data were collected using structured questionnaires, including the National Hospital Seizure Severity Scale (NHS3) and the Medication Adherence Rating Scale (MARS). Associations were analyzed using Spearman correlations, Mann-Whitney U-tests, Kruskal-Wallis tests, and multivariate regression, with p < 0.05 considered statistically significant. Results Among the participants, 300 (65.2%) had DRE. Patients with DRE showed higher seizure severity (NHS3: 15.42 ± 4.86 vs 11.18 ± 3.95, p < 0.001) and lower medication adherence (MARS: 5.92 ± 2.11 vs 8.74 ± 1.96, p < 0.001) than drug-responsive patients. DRE was positively correlated with seizure severity (r = 0.28, p < 0.001) and negatively with adherence (r = -0.22, p < 0.001). Younger adults (18-30 years) exhibited the highest seizure severity and lowest adherence, while adults >60 years had the opposite trend. Multivariate regression identified seizure severity, low adherence, younger age, male gender, longer disease duration, and seizure type as independent predictors of DRE. Conclusion High seizure severity, poor adherence, younger age, and certain seizure characteristics are strongly associated with DRE. Early monitoring, adherence support, and individualized interventions may reduce the burden of persistent seizures in adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.